Pfizer (NYSE:PFE) Stock Price Down 1.3%

Pfizer Inc. (NYSE:PFE - Get Free Report) dropped 1.3% during trading on Friday . The stock traded as low as $28.53 and last traded at $28.53. Approximately 6,583,654 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 42,670,758 shares. The stock had previously closed at $28.92.

Analyst Ratings Changes

Several research firms have weighed in on PFE. BMO Capital Markets restated an "outperform" rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, May 2nd. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 target price for the company. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $35.86.

Pfizer Trading Down 1.0 %

The business's fifty day moving average is $27.17 and its 200-day moving average is $28.04. The stock has a market capitalization of $162.32 billion, a PE ratio of -477.34, a P/E/G ratio of 1.21 and a beta of 0.63. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts' expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer's revenue was down 19.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.23 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.86%. Pfizer's dividend payout ratio (DPR) is -2,799.53%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Briaud Financial Planning Inc acquired a new position in shares of Pfizer during the third quarter worth $30,000. VisionPoint Advisory Group LLC lifted its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 600 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.